At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,535 enrolled
Drug / intervention
IN.PACT Admiral™ Drug Eluting Balloondevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The IN.PACT Global Clinical Study for the Treatment of Comprehensive Superficial Femoral and/or Popliteal Artery Lesions Using the IN.PACT Admiral™ Drug-Eluting Balloon.
In Brief
A clinical study evaluating IN.PACT Admiral™ Drug Eluting Balloon for Peripheral Arterial Disease. Completed, enrolled 1,535 participants across 65 sites in 27 countries.
Detailed Summary
The purpose of this study is to collect safety and efficacy data on the IN.PACT Admiral™ Drug Eluting Balloon (DEB) in treatment of atherosclerotic disease in the superficial femoral and/or popliteal arteries in a "real world" patient population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesArgentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, Egypt, Finland, France, Germany, Greece, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Portugal, Russia, Singapore, Slovakia, Slovenia, South Korea, Sweden, Switzerland, United Kingdom
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedMay 2012
Primary CompletionApr 2016
Study CompletionJan 2020
TodayJul 2026
First PostedMay 31, 2012
Enrollment StartMay 1, 2012
Primary CompletionApr 1, 2016
Study CompletionJan 17, 2020
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 14.1 years ago
Interventions
IN.PACT Admiral™ Drug Eluting Balloondevice
IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.